Media Coverage

Doctors and drug companies are also warming to the medical possibilities of ceramides. Later this year, lab testing giant Quest Diagnostics will start to offer the analysis, potentially making it available to many more patients.

Diagnosing Alzheimer’s disease before symptoms develop may soon be as simple as getting a blood test. New blood tests for certain biomarkers show promise, providing physicians an alternative to expensive scans or invasive spinal taps to make a diagnosis. Quest AD-Detect: Introduced by Quest Diagnostics, this blood test also measures beta-amyloid proteins in your blood to determine your risk for developing Alzheimer’s disease. It does not determine if you have any genetic biomarkers for the disease. The test became available in May 2022, with a cost of $500. There is limited coverage by some health plans.

Although automation and artificial intelligence have long been recognized as a way to improve operational efficiency in clinical laboratories, an industry-wide staffing shortage is creating an added motivation to incorporate more technology. At Secaucus-based Quest Diagnostics, it’s just one of many market forces that is shaping the company’s post-pandemic business strategy.

Medical testing center operator Quest Diagnostics Inc. said that it has begun using a highly automated microbiology lab system that leverages AI to analyze samples. CEO Jim Davis mentioned the platform in the company’s earnings call when he was talking about ways in which it’s trying to counter “significant inflation and wage pressures.”

Do you know your blood type? There’s a good chance that you don’t. More Americans know their horoscope sign (66 percent) than their blood type (51 percent), according to a survey published this year by laboratory company Quest.

Quest Diagnostics, a nationwide medical testing company, will acquire some lab services from New York-Presbyterian in the coming months, the organizations announced Tuesday. The deal will allow physicians affiliated with New York-Presbyterian who work outside of the hospital to send diagnostics for processing to Quest’s laboratory in Clifton, New Jersey. The organizations said they expect to complete the deal in the second quarter of this year, pending regulatory approvals. This acquisition will not affect all testing services. New York-Presbyterian will keep anatomical pathology testing in house along with other diagnostics that require a quick turnaround time, the organizations said.

While tech companies Apple, Amazon and Microsoft took top spots on the 2023 "World's Most Admired Companies" list released by Fortune on Feb. 1, healthcare-related companies were also included. The list, a partnership between Fortune and global management consulting firm Korn Ferry, is based on an analysis of 645 companies in 27 countries. 34 healthcare companies are among the Most Admired Companies in their industries.

EJ Hikel from Northern Light Health and Brandy Dow from Quest Diagnostics talk about blood donation.

Ten years ago, drug overdoses claimed nearly 42,000 lives annually in the United States. By the end of 2021, that number climbed to nearly 108,000. Today, the drug crisis shows no signs of abating, and remains largely fueled by increased access to illicit drugs as well as barriers to healthcare access exacerbated by the COVID-19 pandemic. For the last decade, Quest Diagnostics, through its Health Trends program, has examined insights gleaned from results of our large volume of clinical drug tests, with a goal of empowering better patient care, population health management and informing public health policy.

Anyone who has had medical tests performed likely knows about Quest Diagnostics. The Secaucus-based company is perhaps the most prominent testing company in the world. For this edition of NJBIZ Conversations, Wendi Mader – Quest’s vice president of the commercial employer channel – talks about what it was like to play that role and discusses how she and her staff continue to help businesses identify and mitigate health risks faced by their employees.